Edwards SAPIEN 3 Valve

The SAPIEN 3 TAVI Advantage

The SAPIEN 3 TAVI Advantage

The clear choice for your patients and your TAVI program

Simple
Advanced valve and system designed to simplify procedures

Predictable
Consistent deployment and performance

Proven
Unprecedented evidence for outcomes that matter

See the clinical difference

1.1%
All-cause mortality¹

1.0%
Disabling stroke¹

75%
Lower than surgery¹

* The PARTNER II Trial intermediate-risk cohort 30-day unadjusted clinical event rates for TAVI with the SAPIEN 3 valve, AT population (n=1077).
Simple
Reduced procedural complexity with simplified access, delivery, and deployment.

Predictable
First-time deployment accuracy

Low-Profile Sheath
14F/5.5mm* access without sheath exchanges

Controlled Articulation
The only commercially available transcatheter heart valve to offer controlled articulation

Positioned in the intended location
>99%

Stable, Precise Deployment

Reliable Sealing

No, trace or mild PVL
96.6%

No severe PVL

1. The PARTNER II Trial intermediate-risk cohort 30-day unadjusted clinical event rates for TAVI with the SAPIEN 3 valve, AT population (n=1077).
Proven

Outcomes that matter. Backed by unprecedented evidence, the SAPIEN 3 valve continues to transform today’s treatment of severe aortic stenosis.

1.1% All-cause mortality

1.0% Disabling stroke

Low new permanent pacemaker rates

Designed to allow future coronary access

☑ Excellent long-term durability

Propensity-matched analysis confirms the SAPIEN 3 valve clinical performance in a real-world population


4. Site reported and unadjudicated.
The SAPIEN 3 TAVI Advantage
The clear choice for your patients and your TAVI program.

Simple
Advanced valve and system designed to simplify procedures

Predictable
Consistent deployment and performance

Proven
Unprecedented evidence for outcomes that matter

Discover the SAPIEN 3 TAVI Advantage
SAPIEN3TAVIAdvantage.com